OncoMatch/Clinical Trials/NCT07361107
Evaluation of Circulating Immune Response After Histosonics in Colorectal Cancer (ECHO-CRC)
Is NCT07361107 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies non-drug interventions for colorectal (colon or rectal) cancer.
This is a single-center, non-randomized, open-label, single-arm pilot study investigating the systemic immune response to histotripsy in patients with colorectal cancer with liver metastasis. Histotripsy is an FDA-approved, non-invasive therapeutic modality for the treatment of liver tumors, including both primary and metastatic lesions. In this study, investigators aim to evaluate the kinetics of peripheral T-cell response following histotripsy of colorectal cancer liver metastases (CRCLM). Given the well-documented immune-tolerant tumor microenvironment of liver metastases and their role in systemic resistance to checkpoint inhibitors, investigators hypothesize that histotripsy-induced tumor disruption will lead to measurable alterations in peripheral T-cell clonal expansion and exhaustion markers. Investigators will assess these changes via serial blood draws before and after histotripsy, with the goal of characterizing the systemic immune impact of local tumor ablation. Findings from this study may inform future combination strategies integrating histotripsy with immunotherapy to enhance treatment response in microsatellite-stable CRC
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Disease stage
Metastatic disease required
Performance status
ECOG 0–3(Limited self-care)
Prior therapy
Cannot have received: investigational drug
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1,000/mcL; Platelets ≥ 100,000/mcL
Kidney function
Serum creatinine ≤ 2x ULN unless on dialysis
Liver function
Total bilirubin ≤ 3x ULN (may be up to 5x ULN if Gilbert's syndrome is documented); AST and ALT ≤ 8x institutional ULN
Adequate organ and marrow function as defined below: 1. Absolute neutrophil count: ≥ 1,000/mcL 2. Platelets: ≥ 100,000/mcL 3. Total bilirubin ≤ 3x the upper limit of normal (ULN). This may be up to 5x ULN if Gilbert's syndrome is documented. 4. AST and ALT ≤ 8x institutional ULN. 5. Serum creatinine ≤ 2x ULN unless on dialysis.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Zuckerberg Cancer Center · New Hyde Park, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify